Accro Bioscience was established by a group of industrial veterans and scientists with decades of experience in drug research and development in 2017. Accro Bioscienceis a clinical stage biotech company with the core focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases.
Harnessing the power of disease biology and drug discovery, Accrohas developed a robust portfolio of innovative compounds in various stages spanning from lead optimization to clinical trials.The company's RIPK1 inhibitor AC-003 was approved for clinical trialby FDA and NMPA in December 2021 and August 2022, respectively. AC-003 has completed the Phase I clinical trial inChina and the United States in August 2023 and achieved positive results, and the clinical trial for aGvHD patients is currently undergoing. The Company’s RIKP2 inhibitor AC-101 was approved by HREC in March 2023 for clinical trial.It has completedthe Phase I clinical trial in Australiademonstratingan outstanding safety and PK/PD profile. AC-201, a selective TYK2/JAK1 inhibitor with "Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases, was approved by HREC and NMPA in May 2023 and September 2023.It has completedthe Phase I trial in Australiaand China, and is currently in Phase II clinical trial for patients with moderate to severe plaque psoriasis. The Company has multiple compounds in the PCC and preclinical research stages. The Company owns global rights of all its assets with more than 10 patents issued in major markets includingthe US, the EU, China, Japan, and Korea.
